Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification Matthew FabbroKirah HahnJames F. O’Mahony Systematic Review Open access 30 August 2022 Pages: 773 - 786
The Cost of Flexible Bronchoscopes: A Systematic Review and Meta-analysis Carina Østervig AndersenHelena TravisEmmelie Ploug Jørgensen Systematic Review Open access 22 August 2022 Pages: 787 - 797
Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis Keith B. AllenJames E. AlexanderSusan Gabriel Original Research Article Open access 28 February 2022 Pages: 799 - 809
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer David ElseaLin FanDominic Muston Original Research Article Open access 29 August 2022 Pages: 811 - 822
An EQ-5D-5L Value Set for Belgium Nicolas BouckaertIrina CleemputSophie Gerkens Original Research Article Open access 04 August 2022 Pages: 823 - 836
Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia Fabio GilFabian Juliao-BañosJuan Manuel Reyes Original Research Article Open access 09 August 2022 Pages: 837 - 846
What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care Megan DaleSarah F BellGrace Carolan-Rees Original Research Article Open access 06 September 2022 Pages: 847 - 857
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada Moogeh BaharnooriVirender BhanDaniel Grima Original Research Article Open access 15 September 2022 Pages: 859 - 870
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months Andrew BlauveltNianwen ShiMwangi J. Murage Original Research Article Open access 26 September 2022 Pages: 871 - 880
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin Holly CranmerDavid TruemanTanja Podkonjak Original Research Article Open access 04 September 2022 Pages: 881 - 892
Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates Rachel Milstein BreslauJoshua T. CohenPeter J. Neumann Research Letter Open access 23 July 2022 Pages: 893 - 895
Correction to: Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis Keith B. AllenJames E. AlexanderSusan Gabriel Correction Open access 27 September 2022 Pages: 897 - 897
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer David ElseaLin FanDominic Muston Correction Open access 15 September 2022 Pages: 899 - 899